Novel oral administrated ellagic acid nanoparticles for enhancing oral bioavailability and anti-inflammatory efficacy

Ruan, Jinghua; Yang, Ying; Yang, Fu‐Mei; Wan, Ke; Fan, Dongsheng; Wang, Daoping

doi:10.1016/j.jddst.2018.05.021

Cited by 22 publications

(11 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to counter these flaws, various studies have been made to enhance EA solubility, and several strategies for EA delivery systems were developed over the years [ 27 , 99 , 101 , 102 , 110 , 111 , 112 , 113 , 114 , 115 ]. For example, by complexing EA with cyclodextrins, it is possible to enhance EA’s anti-inflammatory, antioxidant or even antimicrobial properties [ 111 , 114 ].…”

Section: Bioavailability Of Ellagitannins and Ellagic Acidmentioning

confidence: 99%

Recent Advances in the Production and Applications of Ellagic Acid and Its Derivatives. A Review

2020

View full text Add to dashboard Cite

Ellagitannins (ETs), characterized by their diversity and chemical complexity, belong to the class of hydrolysable tannins that, via hydrolysis under acidic or alkaline conditions, can yield ellagic acid (EA). They are mostly found as a part of extractives in angiosperms. As known antioxidants and chelators, EA and EA derivatives are drawing an increasing interest towards extensive technical and biomedical applications. The latter ones include possible antibacterial, antifungal, antiviral, anti-inflammatory, hepato- and cardioprotective, chemopreventive, neuroprotective, anti-diabetic, gastroprotective, antihyperlipidemic, and antidepressant-like activities, among others. EA’s synthesis and production challenges prompt further research on new methods and alternative sources. Conventional and prospective methods and raw materials for the production of EA and its derivatives are reviewed. Among the potential sources of EA, the residues and industrial streams of the pulp industry have been highlighted and considered as an alluring alternative in terms of commercial exploitation.

show abstract

Section: Bioavailability Of Ellagitannins and Ellagic Acidmentioning

confidence: 99%

Recent Advances in the Production and Applications of Ellagic Acid and Its Derivatives. A Review

2020

View full text Add to dashboard Cite

show abstract

“…On the other hand, NCs present some disadvantages, such as weak mechanical properties and complex production procedures. Recently, EA has been successfully encapsulated into NCs made of zein, a group of water insoluble proteins (prolamins) extracted from corn gluten meal [79]. Ruan et al developed a system, characterized by EA and a sacrifice template to form the core and by an outer film of zein mixed with a plasticizer to increase film flexibility.…”

Section: Zein Nanocapsulesmentioning

confidence: 99%

Formulation Strategies to Improve Oral Bioavailability of Ellagic Acid

et al. 2020

View full text Add to dashboard Cite

Ellagic acid, a polyphenolic compound present in fruit and berries, has recently been the object of extensive research for its antioxidant activity, which might be useful for the prevention and treatment of cancer, cardiovascular pathologies, and neurodegenerative disorders. Its protective role justifies numerous attempts to include it in functional food preparations and in dietary supplements, and not only to limit the unpleasant collateral effects of chemotherapy. However, ellagic acid use as a chemopreventive agent has been debated because of its poor bioavailability associated with low solubility, limited permeability, first pass effect, and interindividual variability in gut microbial transformations. To overcome these drawbacks, various strategies for oral administration including solid dispersions, micro and nanoparticles, inclusion complexes, self-emulsifying systems, and polymorphs were proposed. Here, we listed an updated description of pursued micro and nanotechnological approaches focusing on the fabrication processes and the features of the obtained products, as well as on the positive results yielded by in vitro and in vivo studies in comparison to the raw material. The micro and nanosized formulations here described might be exploited for pharmaceutical delivery of this active, as well as for the production of nutritional supplements or for the enrichment of novel foods.

show abstract

“…Regarding the incorporation of ALD into the Talc + Ch hybrid, an enlargement in the band in 1561 cm −1 can be observed, which is attributed to the contribution of amiloride modes due to the interactions between amino groups (–NH 2 ) of Ch and Si–OH of the Talc surface [50]. A similar effect is observed in the band at 1655 cm −1 , attributed to the interaction of the –OH group of Talc and Ch with the –NH group of ALD by hydrogen bonding [49]. In addition, a band appears in 1251 cm −1 , which is very similar to the absorption of 1247 cm −1 in the ALD spectrum, which occurs as well in Talc/ALD and Ch/ALD, indicating the interaction between N–(C 4 N 2 ) and the materials.…”

Section: Resultsmentioning

confidence: 93%

“…When compared to the Ch spectrum, Ch/ALD has a band at 1256 cm −1 intermediate to the 1247 cm −1 observed for ALD and 1262 cm −1 for Ch, which indicates an interaction between the drug N–(C 4 N 2 ) stretch and the amide II of the chitosan, beyond the displacement of the band from 1660 to 1656 cm −1 due to the group interaction of –OH and/or C=O of the amides in Ch with the carbonyl group of ALD by hydrogen bonding [49], confirming the incorporation of the drug.…”

Section: Resultsmentioning

confidence: 99%

Hybrid Systems Based on Talc and Chitosan for Controlled Drug Release

Lima

Coêlho

Silva³

et al. 2019

Materials

View full text Add to dashboard Cite

Inorganic matrices and biopolymers have been widely used in pharmaceutical fields. They show properties such as biocompatibility, incorporation capacity, and controlled drug release, which can become more attractive if they are combined to form hybrid materials. This work proposes the synthesis of new drug delivery systems (DDS) based on magnesium phyllosilicate (Talc) obtained by the sol–gel route method, the biopolymer chitosan (Ch), and the inorganic-organic hybrid formed between this matrix (Talc + Ch), obtained using glutaraldehyde as a crosslink agent, and to study their incorporation/release capacity of amiloride as a model drug. The systems were characterized by X-ray diffraction (XRD), Therma analysis TG/DTG, and Fourier-transform infrared spectroscopy (FTIR) that supported the DDS’s formation. The hybrid showed a better drug incorporation capacity compared to the precursors, with a loading of 55.74, 49.53, and 4.71 mg g−1 for Talc + Ch, Talc, and Ch, respectively. The release assays were performed on a Hanson Research SR-8 Plus dissolver using apparatus I (basket), set to guarantee the sink conditions. The in vitro release tests showed a prolongation of the release rates of this drug for at least 4 h. This result proposes that the systems implies the slow and gradual release of the active substance, favoring the maintenance of the plasma concentration within a therapeutic window.

show abstract

Novel oral administrated ellagic acid nanoparticles for enhancing oral bioavailability and anti-inflammatory efficacy

Cited by 22 publications

References 38 publications

Recent Advances in the Production and Applications of Ellagic Acid and Its Derivatives. A Review

Recent Advances in the Production and Applications of Ellagic Acid and Its Derivatives. A Review

Formulation Strategies to Improve Oral Bioavailability of Ellagic Acid

Hybrid Systems Based on Talc and Chitosan for Controlled Drug Release

Contact Info

Product

Resources

About